Fecal Microbiota Transplantation for Enteric Colitis
Stool donation (FMT) should NOT be used routinely for enteric colitis outside of clinical trials, with the exception of ulcerative colitis where it may be considered on a case-by-case basis only after licensed treatments have failed. 1, 2
Primary Recommendation Based on Guidelines
The 2024 AGA guidelines explicitly recommend against conventional FMT for pouchitis (conditional recommendation, very low certainty) 1, and the 2024 BSG/HIS guidelines state do not offer FMT routinely for non-CDI indications 2. The term "enteric colitis" is broad, but current guideline evidence addresses specific inflammatory bowel conditions:
For Ulcerative Colitis (Most Relevant Evidence)
- Consider FMT only after conventional therapies fail 2
- Moderate evidence shows FMT can induce remission in ulcerative colitis 2
- The 2024 BSG/HIS guidelines permit case-by-case consideration for patients unsuitable for or who have failed licensed treatments 2
- Research meta-analyses show FMT achieves combined clinical and endoscopic remission with OR 3.83 (95% CI: 2.31-6.34) compared to placebo 3
For Crohn's Disease
- Only weak evidence for maintaining remission 2
- Substantial basic research needed before larger trials 1
- Not recommended outside research settings
For Pouchitis
- Weak evidence shows no effect on treatment 2
- Clinical remission rate of 20.1% is comparable to placebo 1
- Explicitly recommended against by AGA 1
Clinical Decision Algorithm
Step 1: Confirm the specific diagnosis
- If ulcerative colitis → proceed to Step 2
- If Crohn's disease or pouchitis → do not offer FMT outside clinical trials 1, 2
Step 2: For ulcerative colitis only, verify treatment history
- Have licensed treatments (5-ASA, corticosteroids, immunomodulators, biologics) been tried and failed?
- Is the patient unsuitable for standard therapies?
- If NO to both → do not offer FMT
- If YES → proceed to Step 3
Step 3: Consider compassionate use criteria 2
- Discuss with gastroenterology specialists experienced in FMT
- Ensure patient understands this is off-label use
- Document that conventional options exhausted
Safety Considerations
Critical caveat: While research shows FMT does not increase adverse events compared to placebo in ulcerative colitis 2, rare severe transmissions have occurred (multidrug-resistant organisms, SARS-CoV-2) 4. One serious adverse event (myasthenia gravis) was reported in long-term follow-up 5.
Post-FMT antibiotic management: Avoid non-CDI antibiotics for at least 8 weeks after FMT, as weak evidence suggests this may cause FMT failure 2. Consult infectious disease specialists if antibiotics are needed during this window 2.
Evidence Quality and Limitations
The evidence diverges significantly by condition. For ulcerative colitis, moderate-quality evidence from multiple RCTs supports efficacy 2, 3, with 25-32% achieving steroid-free remission versus 5-10% with placebo 4. However, long-term maintenance efficacy remains uncertain 4, and optimal protocols (donor selection, delivery route, frequency) are not standardized 1, 6, 7.
For other forms of enteric colitis (Crohn's, pouchitis), evidence is weak to very low quality 1, 2, and guidelines uniformly recommend against routine use.
Bottom Line for Clinical Practice
Do not offer FMT for enteric colitis as routine therapy. The only exception is ulcerative colitis refractory to all licensed treatments, where FMT may be considered through compassionate use programs with specialist consultation 2. For all other forms of enteric colitis, refer patients to clinical trials if FMT is being considered 1.